Lenvatinib

The FDA granted priority review to pembrolizumab plus lenvatinib for treatment of advanced renal cell carcinoma and advanced endometrial carcinoma, according to the agents’ manufacturers.

Lenvatinib plus pembrolizumab improved outcomes vs. chemotherapy for women with advanced endometrial cancer, according to findings presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The combination of lenvatinib and pembrolizumab significantly prolonged OS and PFS compared with sunitinib among previously untreated patients with advanced renal cell carcinoma, according to results of the phase 3 CLEAR trial.

Pembrolizumab plus lenvatinib improved outcomes compared with chemotherapy for women with advanced endometrial cancer, according to topline data released by the agents’ manufacturers.

An 18 mg starting dose of the oral tyrosine kinase inhibitor lenvatinib did not meet the noninferiority requirement compared with the approved, 24 mg starting dose for adults with radioactive iodine-refractory thyroid cancer, data show.

Adults with anaplastic thyroid cancer who received lenvatinib monotherapy experienced some tumor shrinkage but were not considered responders to treatment, suggesting combination therapy should be investigated, researchers reported.